Evofem Biosciences, Inc. (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health. Evofem is leveraging its proprietary Multipurpose Vaginal pH Regulator (MVP-R) to develop product candidates for multiple indications, including the prevention of pregnancy, the prevention of urogenital transmission of chlamydia and gonorrhea in women and the prevention of recurrent bacterial vaginosis.

On Nov. 07, 2018, the company announced its financial results for the quarter ended September 30, 2018 and provided an update on its operations and upcoming milestones.  EVFM have made significant progress this quarter in its clinical programs evaluating Amphora for critical areas in women’s health where current options are either insufficient or absent entirely.

_________________________________________________________________

Happy New Year! 2019 is going to be an exciting year to be a part of our trading group. Do not miss out on our next actionable small cap report. Text the word “Traders” to “25827” and be among the first to know when we initiate coverage. Our latest 2019 member update available here – https://mailchi.mp/tradersnewssource/2019-update-and-direction-for-our-group?e=[UNIQID]

________________________________________________________________________

The Company will have top line Phase 3 data for Empower, at the end of this year and with the positive outcome of its ongoing trial, the company expect to re-file the NDA for Amphora in the second quarter of 2019, which positions the company for FDA action in late 2019 and assuming approval, it will commercialize in January of 2020.

Recent Achievements and Highlights:

• Last patient visit is imminent in AMPOWER, the second Phase 3 trial of Amphora, its lead Multipurpose Vaginal pH Regulator (MVP-R) product candidate, for non-hormonal birth control; anticipating top-line results by year-end 2018;
• Completed ‘User Experience Satisfaction Survey’ among women who completed AMPOWER along with their male partners; and,
• Advanced patient enrollment in Phase 2b clinical trial evaluating the ability of Amphora to prevent urogenital acquisition of Chlamydia trachomatis (primary endpoint) and Neisseria gonorrhea (secondary endpoint) in women (AMPREVENCE).

Upcoming Milestone:

• Top-line data are expected by year-end 2018 from the second Phase 3 clinical trial of Amphora for prevention of pregnancy (AMP002).  Assuming positive results, the Company expects:
• To re-submit the Amphora New Drug Application (NDA) in Q2 2019;
• FDA decision on NDA in Q4 2019 (six-month review);
• To commercialize Amphora in early 2020 as the first and only hormone-free, woman-controlled, ‘only when she needs it’ birth control method (assuming approval).

Milestone Timeline:

Assuming positive results, Evofem will re-submit the Amphora New Drug Application in the second quarter of 2019.  Pending FDA approval, the company expects to launch Amphora in January 2020 as the first and only non-hormonal, on-demand, woman-controlled prescription birth control method in the U.S. If approved, Amphora will be the first innovation in birth control brought to market since the vaginal ring and transdermal patch in 200

Evofem is also conducting a Phase 2b study, AMPREVENCE, to evaluate Amphora for prevention of certain sexually transmitted diseases.  AMPREVENCE is actively enrolling women at U.S. study centers.

Analyst ratings and target price:

Per www.marketbeat.com, Their average twelve-month price target is $10.40, suggesting that the stock has a possible upside of 193.79%. The high price target for EVFM is $15.00, and the low-price target for EVFM is $8.00. There are currently five buy ratings for the stock, resulting in a consensus rating of “Buy.”

Below are the excerpts of recent analyst rating/Price targets on the company:

Source: www.marketbeat.com

About Amphora®: Amphora (L-lactic acid, citric acid, and potassium bitartrate) is an investigational Multi-Purpose Vaginal pH Regulator (MVP-R) designed to regulate vaginal pH within the normal range of 3.5 to 4.5. This maintains an acidic environment which is inhospitable to sperm as well as certain viral and bacterial pathogens associated with sexually transmitted infections but is integral to the survival of healthy bacteria in the vagina.

Market potential and key demand drivers:

• The Company believes that Amphora is the appropriate birth control for many of the 16.5 million women in the U.S. who are not using any form of birth control but do not wish to get pregnant – a population which has indicated significant demand per the Company’s market research. Women who quit their reversible contraception and do nothing for birth control but continue to be sexually active have an 85 percent risk of becoming pregnant within a year.
• If approved by the FDA Amphora will be the first new and innovative birth control method in almost 20 years. It’s unlike anything that has come before it, which makes any comparison to existing therapies very difficult.
• The management believes that the women whose priorities are avoiding hormone, healthy living or who finds side effects of hormonal method unbearable are going to be very attracted to a more natural birth control option that EVFM is going to offer in MVP-R Amphora.
• Also, Amphora’s vaginal pH regulating properties may also be able to prevent the transmission of certain STDs including chlamydia and gonorrhea. The CDC recently reported that rates of gonorrhea and chlamydia have climbed for the fourth consecutive year in the US with nearly 2.3 million cases in 2017.

Financial Results (In thousands):

For the three months ended September 30, 2018, total operating expense was $18.4 million, compared to a total operating expense of $9.1 million for the three months ended September 30, 2017.

Net Loss: Net loss attributable to common stockholders was $110.8 million, or $(5.38) per share, for the nine months ended September 30, 2018, compared with a net loss of $88.7 million, or $(45.23) per share, for the prior year period.

Liquidity and financial flexibility: Unrestricted cash was $12.1 million at September 30, 2018, as compared to $22.8 million at June 30, 2018.  With the treatment and follow-up phase of the AMPOWER study now complete, the Company expects its quarterly cash burn will decrease to approximately $7 to 9 million during the fourth quarter of 2018.

Key Stock Influences:

• Successful completion of the upcoming milestones would lead future direction for the company. Any adversities related to these upcoming milestones might adversely impact the overall investor sentiments.
• EVFM is still an early stage entity and has not yet generated meaningful revenue and will likely operate at a loss as it grows its market position and seeks ways to monetize it.  
• EVFM has a history of operating losses. Therefore, any time or cost overrun in its ongoing R&D activities and its impact on business & financial profile will remain a key business sensitivity factor. 

Stock Chart:

• On Friday January 4^th , EVFM was at $3.89 on volume of 10.3K shares exchanging hands. Market capitalization is $90.535 million. The current RSI is 52.23
• In the past 52 weeks, shares of EVFM have traded as low as $1.7920 and as high as $12.9
• At $3.89, shares of EVFM are trading above its 50-day moving average (MA) at $3.63 and below its 200-day MA at $4.05
• The present support and resistance levels for the stock are at $3.30 & $3.94 respectively. 

Disclaimer

Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.

Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.

This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.

We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.

When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.

17B Disclosure

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.

TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.

Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.